Inactive Instrument

Dermira, Inc.

Equities

US24983L1044

Biotechnology & Medical Research

Dermira, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019

August 07, 2019 at 04:14 pm EDT

Dermira, Inc. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced total revenue was USD 66.645 million compared to USD 39.080 million a year ago. Operating loss was USD 16.302 million compared to USD 21.235 million a year ago. Net loss was USD 17.962 million compared to USD 23.932 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.57 a year ago. For the half year, total revenue was USD 69.097 million compared to USD 39.379 million a year ago. Operating loss was USD 79.024 million compared to USD 78.163 million a year ago. Net loss was USD 82.794 million compared to USD 83.186 million a year ago. Basic loss per share from continuing operations was USD 1.7 compared to USD 1.99 a year ago.

Latest news about Dermira, Inc.

QBREXZA Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Payment to Journey Medical Corporation and $7.5 Million to Dermira Inc	22-02-11	CI
Journey Medical Corp completed the acquisition of Qbrexza from Dermira, Inc.	21-04-29	CI
Journey Medical Corp entered into a definitive agreement to acquire Qbrexza from Dermira, Inc. for $160 million.	21-03-30	CI
Evommune, Inc. Enters into an Exclusive License Agreement with Dermira, Inc	21-01-07	CI
Eli Lilly and Company and Dermira Present New Lebrikizumab Phase 2B Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life	20-06-12	CI
Dermira, Inc. Announces Board Changes	20-02-20	CI
Dermira, Inc.(NasdaqGS:DERM) dropped from S&P Global BMI Index	20-02-20	CI
Dermira, Inc.(NasdaqGS:DERM) dropped from S&P TMI Index	20-02-20	CI
Eli Lilly and Company completed the acquisition of 74.8% stake in Dermira, Inc. from a group of sellers.	20-02-18	CI
Dermira : Eli Lilly profit beat helps ease investor concerns over growth	20-01-30	RE
Dermira : Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO	20-01-16	RE
Eli Lilly and Company entered into an agreement and plan of merger to acquire Dermira, Inc. from a group of sellers for $1.1 billion.	20-01-09	CI
Dermira, Inc. Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis	19-12-10	CI
Transcript : Dermira, Inc. Presents at Piper Jaffray 31st Annual Healthcare Conference, Dec-05-2019 11:00 AM	19-12-05
Transcript : Dermira, Inc. Presents at Evercore ISI 2nd Annual HealthCONx Conference, Dec-04-2019 12:05 PM	19-12-04
Transcript : Dermira, Inc. Presents at Guggenheim Healthcare Talks \| Idea Forum \| Neuro/Immunology Day, Nov-18-2019 09:00 AM	19-11-18
Dermira, Inc. Announces New Scientific Findings Highlighting the Role of Interleukin-13 (IL-13) in Amplifying Itch and the Role Lebrikizumab Plays in Reducing Itch	19-11-14	CI
Dermira, Inc. Announces the Election of Halley E. Gilbert to Its Board of Directors	19-11-13	CI
Transcript : Dermira, Inc., Q3 2019 Earnings Call, Nov 05, 2019	19-11-05
Dermira, Inc. Provides Sales Guidance for Full Year 2019	19-11-05	CI
Dermira, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-05	CI
Transcript : Dermira, Inc. - Special Call	19-10-17
Dermira Presents Data from Phase 2B Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference	19-10-17	CI
Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis	19-10-09	CI
Transcript : Dermira, Inc., Q2 2019 Earnings Call, Aug 07, 2019	19-08-07

Chart Dermira, Inc.

Duration

Period

More charts

Company Profile

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis. The Company's portfolio consists of QBREXZA and Lebrikizumab. QBREXZA is a once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients. QBREXZA is applied directly to the skin and is designed to block underarm sweat production by inhibiting sweat gland activation. Lebrikizumab is an injectable, humanized monoclonal antibody targeting interleukin 13 (IL-13) that the Company is developing for the treatment of moderate-to-severe atopic dermatitis.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+2.97%	108B
REGENERON PHARMACEUTICALS, INC.	+10.21%	105B
ARGENX SE	+1.57%	23.46B
BIONTECH SE	-12.77%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-37.64%	17.45B
BEIGENE, LTD.	-6.50%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+6.00%	13.99B
SAREPTA THERAPEUTICS, INC.	+37.20%	12.53B

Bio Therapeutic Drugs